⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Safety Profile of Semaglutide in People Aged 55 Years and Over: Pooled Data from the PIONEER, SUSTAIN, and STEP Phase 3 Clinical Programmes (P11-9.014)

Marwan Sabbagh Cristina Boschini Sharon Cohen Magnus Fugger Frank Jessen Gabriel Gerardo Martino Sue D. Pedersen Luis Rafael Solís Tarazona Vanita R. Aroda

View at Publisher

Ask AI

Bookmark

Share

Abstract

We investigated the safety of semaglutide in people with T2D and/or overweight/obesity ≥55 years from the phase 3a PIONEER, SUSTAIN and STEP clinical programmes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sabbagh et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678126 https://doi.org/10.1212/wnl.0000000000204711

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the <scp>SUSTAIN</scp> and <scp>PIONEER</scp> Clinical TrialsHuman Clinical Trial · 2026
2Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.Human Clinical Trial · 2026
3Effect of Semaglutide on Body Composition, Physical Function, and Biomarkers of Aging in Older, Overweight Adults with Insulin Resistance: Protocol for an Open-labeled Randomized Controlled Trial (Preprint)2024 · 13 citations
4Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the <scp>STEP</scp> ‐ <scp>HFpEF</scp> programmeRCT · 2025
5Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the <scp>STEP</scp> ‐ <scp>HFpEF</scp> programmeRCT · 2025 · 4 citations

More related papers

Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders2025
752-P: Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics—Post Hoc Analysis of PIONEER 11 and 122024
Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 62025

More from Neurology

Blood-Based Biomarkers as Predictors of All-Cause DementiaFri,
Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,